Cardiomyocytes Deficiency of SENP1 Promotes Myocardial Fibrosis via Paracrine Action

Zhihao Liu, Xiyun Bian, Lan Li, Li Liu, Chao Feng, Ying Wang, Jingyu Ni, Sheng Li, Dading Lu, Yanxia Li, Chuanrui Ma, Tian Yu, Xiaolin Xiao, Na Xue, Yuxiang Wang, Chunyan Zhang, Xiaofang Ma, Xiumei Gao, Xiaohui Fan, Xiaozhi Liu, Guanwei FanbioRxiv 2023 · DOI

TL;DR

This study reveals that SENP1, a protease involved in protein modification, is crucial for maintaining heart health after myocardial infarction (MI). Its deficiency in heart muscle cells (cardiomyocytes) leads to fibrosis and dysfunction by promoting a signaling cascade involving fibronectin and STAT3, mediated by HSP90ab1. Targeting HSP90ab1 SUMOylation offers a promising therapeutic avenue for reversing cardiac remodeling post-MI.

What Problem Does This Paper Address?

Myocardial infarction (MI), commonly known as a heart attack, often leads to pathological remodeling of the heart, characterized by fibrosis (scarring) and progressive heart failure. While the general mechanisms of this remodeling are known, the specific molecular players and pathways that govern this process, particularly at the cellular level, remain incompletely understood. This gap hinders the development of effective therapeutic strategies to reverse or prevent this detrimental remodeling. This paper specifically investigates the role of SENP1, a protease that regulates protein SUMOylation, in cardiomyocytes following MI, aiming to clarify its contribution to maladaptive cardiac remodeling.

Methods

The researchers employed a multi-pronged approach:

  • Genetic Manipulation: They generated cardiomyocyte-specific SENP1 knockout and overexpression mouse models to study the effects of SENP1 deficiency and abundance in heart muscle cells.
  • In Vitro Studies: Adult mouse cardiomyocytes and fibroblasts were isolated and cultured to investigate paracrine signaling (communication between cells).
  • Proteomics: DIA (Data-Independent Acquisition) proteomic assays and mass spectrometry were used to identify differential proteins in cardiomyocytes and search for key effector proteins regulated by SENP1.
  • Single-Cell Sequencing: Single-cell RNA sequencing data were analyzed to pinpoint specific cardiomyocyte clusters affected by SENP1 after MI.
  • Molecular Assays: Western blotting, immunofluorescence staining, and co-immunoprecipitation were used to assess protein expression, localization, interactions, and post-translational modifications (like SUMOylation and phosphorylation).
  • Animal Models: Mouse models were subjected to MI (induced by coronary artery ligation) to evaluate cardiac function (echocardiography) and cardiac fibrosis (histological staining).
  • Gene Therapy: Adeno-associated virus (AAV) vectors were used for gene delivery to overexpress SENP1 or mutate specific sites on HSP90ab1 in cardiomyocytes.

Datasets

Not explicitly detailed as distinct datasets for training or evaluation in the context of machine learning. The study utilized:

  • Mouse heart snRNA-seq data: Analyzed to understand SENP1 expression across different cell types in the heart.
  • Published ChIP-seq data: Used to identify STAT3 binding sites within the Fn promoter.

Key Insights and Ideas

  • SENP1's Protective Role in MI: The study strongly suggests SENP1 is not just a general regulator of SUMOylation but plays a critical protective role in the heart post-MI. Its downregulation is a key event leading to fibrosis.
  • Cardiomyocyte-Fibroblast Crosstalk is Key: The research highlights how SENP1 deficiency in cardiomyocytes triggers a paracrine signaling cascade that directly impacts fibroblasts, driving fibrosis. This emphasizes the importance of cell-cell communication in cardiac remodeling.
  • HSP90ab1 as a Central Mediator: The identification of HSP90ab1 as a key downstream target of SENP1, linking SENP1 to STAT3 activation and subsequent fibronectin production, provides a crucial mechanistic link.
  • SUMOylation of HSP90ab1 is a Therapeutic Target: The finding that blocking SUMOylation at the Lys72 site of HSP90ab1 can reverse the fibrotic effects and improve cardiac function opens up a novel therapeutic strategy.

Key Results

  • SENP1 expression was significantly reduced in post-infarction mouse hearts and in patients with heart failure.
  • Cardiomyocyte-specific SENP1 deficiency led to increased myocardial fibrosis and progressive cardiac dysfunction.
  • SENP1 overexpression improved cardiac function and reduced fibrosis.
  • SENP1 deficiency in cardiomyocytes promoted fibronectin (Fn) expression and secretion, which in turn activated fibroblasts.
  • Mechanistically, SENP1 promotes the deSUMOylation and degradation of HSP90ab1, which reduces STAT3 phosphorylation and Fn transcription.
  • Blocking HSP90ab1 SUMOylation at the Lys72 site ameliorated adverse ventricular remodeling and dysfunction post-MI.

Limitations and Future Work

  • Whole Heart vs. Cell-Specific: While previous studies looked at SENP1 in the whole heart, this study focused on cardiomyocytes. However, the complex interplay with other cardiac cell types (e.g., inflammatory cells) during the initial stages of MI warrants further investigation.
  • In Vivo Validation of Therapeutic Target: While the study demonstrates the potential of targeting HSP90ab1 SUMOylation, further preclinical and clinical studies are needed to fully validate this as a therapeutic strategy.
  • Broader Roles of SENP1: The study focuses on SENP1's role in MI. Its broader functions in other cardiovascular conditions or its interactions with other signaling pathways could be explored.
  • Specific SUMOylation Pathways: While the study identifies HSP90ab1 Lys72 as a critical SUMOylation site, a deeper dive into the specific SUMOylation machinery involved could be beneficial.

Summary updated

Abstract

Abstract Background SENP1 (Sentrin-specific protease 1) is involved in heart disease by regulating intracellular SUMOylation. However, the role of cell type-specific SENP1 in the setting of myocardial infarction (MI) remains to be defined. We determined whether cardiomyocyte-specific SENP1 regulates maladaptive remodeling in the ischemic heart. Methods We generated cardiomyocyte-specific SENP1 knockout and overexpression mice to assess cardiac function and ventricular remodeling responses under physiological and pathological conditions. Adult mouse cardiomyocytes and fibroblasts were separated to observe the paracrine effects of cardiomyocytes. DIA proteomic assay and bioinformatic analysis were performed to detect differential proteins in primary cardiomyocytes. Single-cell sequencing data were analyzed to identify key cardiomyocyte cluster regulated by SENP1 after MI. Mass spectrometry was performed to search for key effector proteins regulated by SENP1. Results SENP1 expression reduced in post-infarction mice and patients with heart failure. Cardiomyocyte-specific SENP1 deficiency (genetic or adeno-associated virus (AAV)-mediated) triggered a myocardial fibrotic response and progressive cardiac dysfunction. MI exacerbated the poor ventricular remodeling response mediated by SENP1 deletion, SENP1 overexpression improved cardiac function and reduced fibrosis. Further, we found that increased cardiac fibrosis in the cardiomyocyte-specific SENP1 deletion mice, associated with increased Fn expression and secretion in cardiomyocytes, promoted fibroblast activation in response to myocardial injury. Mechanistically, SENP promoted deSUMOylation of the HSP90ab1 (heat shock protein 90 alpha, class B, member 1) Lys72 and ubiquitin-dependent degradation, which reduced HSP90ab1-mediated phosphorylation of STAT3 (signal transducer and activator of transcription 3) and transcriptional activation of Fn, and then reduced fibroblast activation in the indirect coculture model. On the other hand, AAV-mediated mutation of the HSP90ab1 Lys72 ameliorated adverse ventricular remodeling and dysfunction post-MI. Conclusions SENP1 is essential for repressing STAT3-mediated Fn transcription by regulating deSUMOylation of HSP90ab1. Blockade of HSP90ab1 SUMOylation at the Lys72 site is a novel therapy effective in reversing adverse ventricular remodeling post-MI. Abstract Figure
BibTeX
@misc{liu2023cardiomyocytes,
  author = {Zhihao Liu and Xiyun Bian and Lan Li and Li Liu and Chao Feng and Ying Wang and Jingyu Ni and Sheng Li and Dading Lu and Yanxia Li and Chuanrui Ma and Tian Yu and Xiaolin Xiao and Na Xue and Yuxiang Wang and Chunyan Zhang and Xiaofang Ma and Xiumei Gao and Xiaohui Fan and Xiaozhi Liu and Guanwei Fan},
  title = {{Cardiomyocytes Deficiency of SENP1 Promotes Myocardial Fibrosis via Paracrine Action}},
  year = {2023},
  doi = {10.1101/2023.06.21.546019},
  howpublished = {bioRxiv},
}
Figure